GLIS2 Downregulation Therapy for ADPKD Cyst Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autosomal dominant polycystic kidney disease (ADPKD) like tolvaptan have significant side effects and are not suitable for long-term use, necessitating the development of novel therapies.
Innovation Solution
Administering compounds that downregulate GLIS2, such as protein inhibitors, nucleic acids, ribozymes, or antibodies, to target the underlying genetic cause of ADPKD, including GLIS2 downregulation via RNA interference or CRISPR knockout.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tolvaptan is administered to treat ADPKD, then cyst growth is inhibited, but severe side effects occur including polyuria, hepatic injury, and other adverse reactions
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (GLIS2 transcription factor) that drives cyst formation in ADPKD, rather than using tolvaptan's broad V2-receptor antagonism. By administering compounds that specifically downregulate GLIS2 (such as small molecules, siRNAs, or antibodies), the treatment achieves cyst growth inhibition through a targeted pathway while avoiding the off-target effects responsible for tolvaptan's severe side effects including polyuria and hepatic injury
Solution Approach 2:
The patent changes the therapeutic parameter from V2-receptor antagonism to GLIS2 downregulation. This parameter change involves administering compounds that specifically reduce GLIS2 expression or activity (such as siRNAs, antisense oligonucleotides, or small molecule inhibitors), thereby altering the mechanism of action to achieve cyst growth inhibition through a different molecular pathway that does not produce tolvaptan's harmful effects
2Duration of action of stationary object
If tolvaptan is used for long-term treatment of ADPKD, then cyst progression is slowed, but cumulative side effects and toxicity increase
Solution Approach 1:
The patent extracts the specific downstream target (GLIS2) that mediates cyst formation, allowing for targeted long-term therapy. By administering GLIS2-downregulating compounds with favorable safety profiles for chronic administration, the treatment can be maintained over extended periods without the cumulative hepatotoxicity and other toxicities associated with long-term tolvaptan use
Solution Approach 2:
The patent employs compounds with favorable pharmacokinetic and safety profiles that allow repeated or continuous administration. The use of GLIS2-targeting agents (such as siRNAs or small molecules) replaces tolvaptan, enabling long-term treatment strategies without the cumulative side effects that limit tolvaptan's duration of use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces cyst formation and progression of ADPKD, alleviating kidney damage and improving kidney function without the severe side effects associated with existing medications.
Implementation Method 1
a nucleic acid that down regulates GLIS2 by RNA interference
Implementation Method 2
an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that down regulates GLIS2 by CRISPR knockout or CRISPR knock down
Data Source
AI summary
Described herein is a method for treating, ameliorating and/or preventing polycystic kidney disease in a subject in need thereof. The method including administering to the subject an effective amount of a compound that downregulates GLIS2. Also described herein are a composition and a kit for performing the method, and a method of screening suppressors of downstream effects of loss of PKD1 or PKD2.